| Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells P Rajendran, E Ho, DE Williams, RH Dashwood Clinical epigenetics 3, 1-23, 2011 | 228 | 2011 |
| HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates P Rajendran, AI Kidane, TW Yu, WM Dashwood, WH Bisson, CV Löhr, ... Epigenetics 8 (6), 612-623, 2013 | 137 | 2013 |
| Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly P Rajendran, B Delage, WM Dashwood, TW Yu, B Wuth, DE Williams, ... Molecular cancer 10, 1-19, 2011 | 135 | 2011 |
| Betulinic acid and its derivatives as anti-angiogenic agents R Mukherjee, M Jaggi, P Rajendran, MJA Siddiqui, SK Srivastava, ... Bioorganic & medicinal chemistry letters 14 (9), 2181-2184, 2004 | 101 | 2004 |
| Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity P Rajendran, M Jaggi, MK Singh, R Mukherjee, AC Burman Investigational new drugs 26, 25-34, 2008 | 94 | 2008 |
| Metabolism as a key to histone deacetylase inhibition P Rajendran, DE Williams, E Ho, RH Dashwood Critical reviews in biochemistry and molecular biology 46 (3), 181-199, 2011 | 87 | 2011 |
| HDAC8 and STAT3 repress BMF gene activity in colon cancer cells Y Kang, H Nian, P Rajendran, E Kim, WM Dashwood, JT Pinto, ... Cell death & disease 5 (10), e1476-e1476, 2014 | 80 | 2014 |
| Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity B Chetan, M Bunha, M Jagrat, BN Sinha, P Saiko, G Graser, T Szekeres, ... Bioorganic & medicinal chemistry letters 20 (13), 3906-3910, 2010 | 76 | 2010 |
| Histone and non-histone targets of dietary deacetylase inhibitors E Kim, W H Bisson, C V Lohr, D E Williams, E Ho, R H Dashwood, ... Current topics in medicinal chemistry 16 (7), 714-731, 2016 | 71 | 2016 |
| Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon P Rajendran, WM Dashwood, L Li, Y Kang, E Kim, G Johnson, KA Fischer, ... Clinical epigenetics 7, 1-12, 2015 | 61 | 2015 |
| Biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions AC Burman, R Mukherjee, D Khattar, S Mullick, M Jaggi, MK Singh, ... US Patent 8,927,023, 2015 | 58 | 2015 |
| Heterocyclic analogs of sulforaphane trigger DNA damage and impede DNA repair in colon cancer cells: interplay of HATs and HDACs A Okonkwo, J Mitra, GS Johnson, L Li, WM Dashwood, ML Hegde, C Yue, ... Molecular nutrition & food research 62 (18), 1800228, 2018 | 57 | 2018 |
| Discovery of adamantane based highly potent HDAC inhibitors B Gopalan, T Ponpandian, V Kachhadia, K Bharathimohan, R Vignesh, ... Bioorganic & medicinal chemistry letters 23 (9), 2532-2537, 2013 | 54 | 2013 |
| Synthesis of 3-O-acyl/3-benzylidene/3-hydrazone/3-hydrazine/17-carboxyacryloyl ester derivatives of betulinic acid as anti-angiogenic agents R Mukherjee, M Jaggi, P Rajendran, SK Srivastava, MJA Siddiqui, ... Bioorganic & medicinal chemistry letters 14 (12), 3169-3172, 2004 | 52 | 2004 |
| Synthesis and Evaluation of 4/5-Hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-Restricted Analogues of Combretastatin A-4 as Novel Anticancer … MK Gurjar, RD Wakharkar, AT Singh, M Jaggi, HB Borate, PD Shinde, ... Journal of medicinal chemistry 50 (8), 1744-1753, 2007 | 50 | 2007 |
| Synthesis and cytotoxic activity of 3-O-acyl/3-hydrazine/2-bromo/20, 29-dibromo betulinic acid derivatives R Mukherjee, M Jaggi, MJA Siddiqui, SK Srivastava, P Rajendran, ... Bioorganic & medicinal chemistry letters 14 (15), 4087-4091, 2004 | 46 | 2004 |
| A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphane‐treated colon cancer cells GS Johnson, J Li, LM Beaver, WM Dashwood, D Sun, P Rajendran, ... Molecular nutrition & food research 61 (4), 1600769, 2017 | 44 | 2017 |
| Acetylation of CCAR2 establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition P Rajendran, G Johnson, L Li, YS Chen, M Dashwood, N Nguyen, ... Cancer research 79 (5), 918-927, 2019 | 36 | 2019 |
| Betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis M Jaggi, S Ramadoss, P Rajendran, MJA Siddiqui US Patent 6,403,816, 2002 | 28 | 2002 |
| Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam FU Ertem, W Zhang, K Chang, W Mohaiza Dashwood, P Rajendran, ... International journal of cancer 140 (2), 460-468, 2017 | 26 | 2017 |
